Cargando…

Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway

BACKGROUND: We investigated the role of the ETS-1 transcription factor in Head and Neck Squamous Cell Carcinoma (HNSCC) in multiple cisplatin-resistant HNSCC cell lines. METHODS: We examined its molecular link with SRC and MEK/ERK pathways and determined the efficacy of either MEK/ERK inhibitor PD03...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Zejia, Liao, Jipei, Carter-Cooper, Brandon A., Lapidus, Rena G., Cullen, Kevin J., Dan, Hancai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532223/ https://www.ncbi.nlm.nih.gov/pubmed/31118072 http://dx.doi.org/10.1186/s12885-019-5664-7

Ejemplares similares

Inhibition of IKKβ/NF-κB signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma
por: Yang, Zejia, et al.
Publicado: (2020)

Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer
por: Li, Zhipeng, et al.
Publicado: (2018)

A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-κB regulates head and neck squamous cell carcinoma proliferation
por: Li, Zhipeng, et al.
Publicado: (2016)

The Differential Impact of SRC Expression on the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma
por: Hermida-Prado, Francisco, et al.
Publicado: (2019)

SDCBP Modulates Stemness and Chemoresistance in Head and Neck Squamous Cell Carcinoma through Src Activation
por: Mir, Cristina, et al.
Publicado: (2021)

Decitabine Rescues Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma
por: Viet, Chi T., et al.
Publicado: (2014)

Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck.
por: KjellÃ©n, E., et al.
Publicado: (1989)

Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas
por: Griso, Ana Belén, et al.
Publicado: (2022)

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
por: Rades, Dirk, et al.
Publicado: (2023)

Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma
por: Lang, Liwei, et al.
Publicado: (2019)

Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance
por: Liu, Shutong, et al.
Publicado: (2017)

MicroRNA-21 induces cisplatin resistance in head and neck squamous cell carcinoma
por: Sheng, Shuyan, et al.
Publicado: (2022)

Eligibility criteria to cisplatin in head and neck squamous cell carcinoma: Egyptian expert opinion
por: Abdulla, Mohamed, et al.
Publicado: (2023)

Transcriptomic and Proteomic Profiles for Elucidating Cisplatin Resistance in Head-and-Neck Squamous Cell Carcinoma
por: Garcia-Mayea, Yoelsis, et al.
Publicado: (2022)

Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States
por: Aggarwal, Himani, et al.
Publicado: (2020)

Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients
por: Ferreira, Ana Maria Castro, et al.
Publicado: (2023)

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells
por: Martens-de Kemp, Sanne R., et al.
Publicado: (2013)

Feasibility of Cisplatin/5-Fluorouracil and Panitumumab in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck
por: Tahara, Makoto, et al.
Publicado: (2014)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma
por: Jacinto, Alexandre Arthur, et al.
Publicado: (2018)

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review
por: Peddi, Prakash, et al.
Publicado: (2015)

Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
por: Longton, Eleonore, et al.
Publicado: (2018)

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Kim, Moon Jin, et al.
Publicado: (2019)

Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma
por: Shinohara, Shogo, et al.
Publicado: (2021)

Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC)
por: Zhang, Fugui, et al.
Publicado: (2017)

Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas
por: Veracini, Laurence, et al.
Publicado: (2014)

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
por: Shimada, Rie, et al.
Publicado: (2018)

Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma
por: Jiang, Minghong, et al.
Publicado: (2011)

NM23-H1 expression of head and neck squamous cell carcinoma in association with the response to cisplatin treatment
por: Wang, Yi-Fen, et al.
Publicado: (2014)

S-nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma()
por: Kaliyaperumal, Kolanjiappan, et al.
Publicado: (2015)

Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma
por: Bryant, Jennifer, et al.
Publicado: (2019)

Acquisition of Cisplatin Resistance Shifts Head and Neck Squamous Cell Carcinoma Metabolism toward Neutralization of Oxidative Stress
por: Yu, Wangjie, et al.
Publicado: (2020)

Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy
por: Porceddu, Sandro V., et al.
Publicado: (2020)

Cisplatin effect on head and neck squamous cell carcinoma cells is modulated by ERK1/2 protein kinases
por: Bostan, Marinela, et al.
Publicado: (2019)

p53‐independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells
por: Sharma, Kanika, et al.
Publicado: (2018)

Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors
por: Egloff, Ann Marie, et al.
Publicado: (2009)

Mammalian target of rapamycin and head and neck squamous cell carcinoma
por: Liao, Yu-Min, et al.
Publicado: (2011)

Prostaglandin-like material extracted from squamous carcinomas of the head and neck.
por: Bennett, A., et al.
Publicado: (1980)

Polymorphisms in DNA mismatch repair pathway genes predict toxicity and response to cisplatin chemoradiation in head and neck squamous cell carcinoma patients
por: Nogueira, Guilherme Augusto Silva, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_468hl2p1da6t76u0gutghd7fae